Currently, no generic Lexiva products are licensed for sale. However, generic versions may be introduced once the patent expires in June 2018. Until an approved generic version is available, you should not buy any so-called "generic Lexiva" because these products may be fake, substandard, and potentially dangerous.
Generic Lexiva: An Overview
Lexiva® (fosamprenavircalcium) is a prescription AIDS and HIV medication. It belongs to a class of medications known as protease inhibitors and is approved only for use along with other HIV medications.
Lexiva is made by GlaxoSmithKline. It is currently under the protection of patents that prevent any generic Lexiva from being manufactured in the United States. Yet, if you search the Internet for "generic Lexiva," you may find a number of companies selling it. The fact is that these medicines may be fake, substandard, and potentially dangerous. Generic Lexiva may be available from another country, but there is really no way of knowing whether you are actually getting genuine Lexiva. You should not buy any generic Lexiva until there is an approved version available.
When Will Generic Lexiva Be Available?
The first patent for Lexiva currently expires in June 2018. This is the earliest possible date that a generic version of the drug could become available. However, other circumstances could come up to extend the exclusivity period beyond 2018. This could include such things as other patents for specific Lexiva uses or lawsuits. Once the patent expires, several companies will likely begin manufacturing a generic Lexiva drug.
Is Fosamprenavir the Same as Generic Lexiva?
No -- fosamprenavir is the active ingredient in Lexiva, but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Lexiva [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2013 February.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed May 31, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click